B-cell receptor complex (BCR) (BCR)

The B-cell receptor (BCR) complex is a multi-subunit transmembrane structure on B-lymphocytes essential for antigen recognition and the initiation of humoral immunity (Nature Reviews Immunology, 2010). It consists of a membrane-bound immunoglobulin (mIg) molecule, such as IgM, which provides antigen specificity, and a signaling heterodimer composed of CD79A (Ig-alpha) and CD79B (Ig-beta) (UniProt P11912, P40259). Associated IgM-binding receptors, most notably the Fc receptor for IgM (FcμR/CD351), interact with the BCR to modulate signaling thresholds and maintain B-cell homeostasis (Journal of Immunology, 2014). In various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), the BCR complex often exhibits constitutive or hyperactive signaling that promotes tumor cell survival and proliferation (Blood, 2012). Therapeutic targeting of the BCR complex includes the use of antibody-drug conjugates like Polatuzumab vedotin, which targets CD79B, and small molecule inhibitors like Ibrutinib that target downstream components like Bruton's tyrosine kinase (BTK) (FDA Label, 2019). These interventions aim to disrupt the survival signals provided by the BCR, leading to B-cell depletion or growth arrest in pathogenic contexts. Safety concerns associated with targeting this complex primarily involve profound B-cell depletion and subsequent immunosuppression, increasing the risk of opportunistic infections.

Other names

B-cell antigen receptorBCR complexCD79A/CD79B complexSurface immunoglobulin complexIgM receptor complexFc receptor for IgM (FcμR)CD351

Targeting of the BCR complex involves either direct binding to structural components like CD79B to deliver cytotoxic payloads (e.g., antibody-drug conjugates) or the inhibition of downstream signaling kinases such as Bruton's tyrosine kinase (BTK) and Spleen tyrosine kinase (SYK) to block survival and proliferation signals (Nature Reviews Drug Discovery, 2017).